Sebical 10/40 mg
Olmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Korea Sintex Pharmaceutical Co., Ltd.
MFDS item code 201907787 · Approved 2019.11.07
This product's status changed to Expired on 2024.11.07. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of essential hypertension not controlled by monotherapy
This medication is used for patients with essential hypertension whose blood pressure is not adequately controlled by monotherapy with amlodipine or olmesartan medoxomil. Essential hypertension refers to a condition where blood pressure is consistently high, and it is important to reduce the risk of cardiovascular complications through appropriate treatment. This medication effectively lowers blood pressure and helps protect the heart and blood vessels. Therefore, it is used in the treatment of essential hypertension.
Take 1 tablet once daily with water, with or without food. It is recommended that the medication be taken at the same time each day (e.g., in the morning), if possible. Before starting this medication, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to this medication may be considered. The maximum dose of this medication is 10/40 milligrams. Since the maximum blood pressure-lowering effect occurs within 2 weeks of administration, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 milligrams: For patients whose blood pressure is not adequately controlled with monotherapy using amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams. - 10/20 milligrams: For patients whose blood pressure is not adequately controlled with monotherapy using olmesartan medoxomil 20 milligrams. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This medication has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily, and this medication is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients on dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: For patients who may have reduced effective intravascular volume (e.g., patients taking diuretics, especially those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medication should not be administered to patients with severe hepatic impairment. (See section 2. Patients who should not take this medication under Precautions for Use.) ∘Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients.
∘Children: Safety and efficacy have not been established in pediatric patients under 18 years of age.
This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it must be discontinued immediately upon confirmation of pregnancy. It should not be used by individuals with allergies to the active ingredients or similar components, pregnant or nursing women, patients with severe liver impairment, aortic stenosis, bile duct obstruction, patients undergoing dialysis, patients in shock, or certain diabetic patients. Patients with low blood pressure due to a lack of fluid or salt may experience symptoms of hypotension, so careful monitoring is required when starting the medication. Significant vasodilation may lead to hypotension, so patients with heart or vascular issues should be cautious. Caution is required for patients with heart failure, and those with impaired kidney function should be closely monitored for changes in kidney function while on this medication. This medication may cause side effects such as dizziness, headache, hypotension, orthostatic hypotension, drowsiness, nausea, edema, and rash. Particularly, potassium levels may increase, so regular monitoring of potassium levels is necessary. Patients on beta-blockers should avoid sudden discontinuation and taper off doses gradually; this medication is not a beta-blocker. When used in conjunction with other antihypertensives, the blood pressure-lowering effects may be increased, so it should be taken as directed by a physician. Taking this medication with grapefruit juice may enhance the blood pressure-lowering effects, so it is advisable to avoid it. It should not be used during pregnancy; if planning pregnancy or if pregnancy is confirmed, consultation with a physician is mandatory. Nursing women are advised to stop breastfeeding or discontinue the medication, as it may pass into breast milk. Safety and efficacy have not been established in pediatric patients under 18 years old, so its use is not recommended. Elderly patients should start with a low dose, considering potential kidney and liver function decline, and should be cautious while taking it. In cases of overdose, symptoms such as hypotension and cardiac arrhythmias may occur, and immediate medical assistance should be sought; blood pressure and cardiac function should be monitored regularly. This medication should be stored in a tightly sealed container away from moisture, heat, and direct sunlight, out of the reach of children.
Not everyone experiences these, and they can vary from person to person.
This medication should be kept in a tightly sealed container to avoid exposure to air or moisture. The recommended storage temperature is between 1 to 30 degrees Celsius at room temperature.
Red-brown round film-coated tablet
28/PTP[(14 tablets/PTP x 2)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Olmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Korea Sintex Pharmaceutical Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.